Want to see GB:AVCT full AI Analyst Report?
Top Page
Avacta Group plc
(LSE:AVCT)
Select Model
Select Model
Rating:50Neutral
Price Target:
64.00 p
▼(-0.78% Downside)
Action:Reiterated
Date:05/26/26
The score is held down primarily by weak financial performance (ongoing losses, cash burn, and balance-sheet pressure). Technicals provide moderate support with price above longer-term averages and a positive MACD, while valuation remains challenged due to negative earnings and no dividend. The earnings call adds some offsetting strength from clinical progress and improved cash management, but near-term financing/partnering dependency and timeline risks remain material.
Positive Factors
Clinical pipeline execution
On-time AVA6103 dosing and continued AVA6000 development demonstrate execution across the lead pipeline. Defined expansion dosing and planned clinical readouts create identifiable milestones that could support partnering and future commercialisation.
Negative Factors
Persistent losses and cash burn
Avacta remains dependent on external capital while funding expensive clinical programmes. Persistent negative cash generation limits financial flexibility and means future dilution or partnering proceeds may be needed before products generate meaningful operating revenue.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical pipeline execution
On-time AVA6103 dosing and continued AVA6000 development demonstrate execution across the lead pipeline. Defined expansion dosing and planned clinical readouts create identifiable milestones that could support partnering and future commercialisation.
Read all positive factors
Avacta Group plc (AVCT) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£299.78M
Dividend YieldN/A
Average Volume (3M)3.07M
Price to Earnings (P/E)―
Beta (1Y)0.73
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees81
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding471,330,500
10 Day Avg. Volume4,236,507
30 Day Avg. Volume3,069,625
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)93.68
Price to Sales (P/S)2052.69
P/FCF Ratio-9.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.07
Revenue Forecast (FY)N/A
Avacta Group plc Business Overview & Revenue Model
Company Description
Avacta Group Plc operates as a clinical-stage biopharmaceutical company, specializing in the development of cancer therapies and diagnostic solutions. These advancements are driven by its proprietary Affimer and pre|CISION technology platforms, wi...
How the Company Makes Money
Avacta makes money primarily through (1) collaboration and partnering income and (2) product and service revenues from its diagnostics-related activities, with additional potential upside from future commercialisation of therapeutics if/when candi...
Avacta Group plc Earnings Call Summary
Earnings Call Date:May 19, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Oct 05, 2026
Earnings Call Sentiment Positive
The call presented multiple important positive developments: on-time clinical execution (first-in-human dosing for AVA6103), promising preclinical metrics (up to ~40x tumor Cmax and ~3x tumor selectivity), strengthened IP, focused R&D investment (+31.5% YoY), cost reductions and a successful recent fundraising that extends runway into early Q1 2027. Offsetting these positives are meaningful near-term financing and timeline risks — limited cash runway without partner income, dependence on partnership to launch pivotal studies, tolerability/dose-selection questions at higher AVA6000 doses, and delays/hold status for the Affimer program. On balance the call emphasized substantive scientific and clinical progress alongside manageable but material financing and timing risks.Positive Updates
Clinical Milestone — AVA6103 First Patient Dosed
First patient dosed in FOCUS-01 Phase I (AVA6103) on time in March 2026; multicenter US-focused trial enrolling 6 advanced cancers with initial clinical data committed by end of 2026 (late Q4).
Negative Updates
Limited Near-Term Cash Runway and Financing Dependency
Cash balance of GBP 16.4m provides runway only into early Q1 2027 assuming no partnering income; company did not disclose monthly burn and remains dependent on further financing or partnerships to fund clinical development beyond that point.
Read all updates
Q4-2025 Updates
Positive
Negative
Clinical Milestone — AVA6103 First Patient Dosed
First patient dosed in FOCUS-01 Phase I (AVA6103) on time in March 2026; multicenter US-focused trial enrolling 6 advanced cancers with initial clinical data committed by end of 2026 (late Q4).
Read all positive updates
Company Guidance
The call guided a busy 2026 timetable and detailed financial and clinical metrics: R&D spend was GBP 18.8m in FY2025 (up from GBP 14.3m), administrative costs ~GBP 10m (down from GBP 12m), net operating cash outflow GBP 22.64m (vs GBP 24.94m in 2024), and the company has raised GBP 32.5m over the last 18 months (including an oversubscribed GBP 10m placing), leaving cash of GBP 16.4m at end-April 2026 and a runway into early Q1 2027 (assumes no partnering income). Clinically, AVA6103 (FOCUS‑01) dosed its first patient on time in March 2026, is enrolling across ~7–9 U.S. Phase Ia sites for six advanced tumor types (no UK centers), and initial Phase I data are expected by end‑2026 (late Q4); AVA6000 continues in Phase Ia/Ib with a recommended dose for expansion of 310 mg/m2 (other cohorts: 385, 385/200, 250) and Phase Ib/efficacy and cardiac‑safety data to be presented H1 2026 (ASCO/BIO). Pipeline timing also includes AVA6207 payload disclosures targeted in Q3 2026 and candidate selection in H2 2026; preclinical metrics cited include up to 40x higher tumor Cmax for released exatecan versus daruxtecan and ~3x higher tumor selectivity index versus ADCs, and the platform targets FAP expressed in ~90% of solid tumors.Avacta Group plc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
27
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 113.00K | 113.00K | 2.85M | 9.65M | 2.94M |
| Gross Profit | -1.17M | 113.00K | 2.84M | 4.23M | -2.50M |
| EBITDA | -28.96M | -17.62M | -14.12M | -34.78M | -26.69M |
| Net Income | -38.38M | -52.84M | -24.95M | -36.94M | -26.32M |
Balance Sheet | |||||
| Total Assets | 29.42M | 48.27M | 73.19M | 92.65M | 47.00M |
| Cash, Cash Equivalents and Short-Term Investments | 16.86M | 12.87M | 16.63M | 41.78M | 26.19M |
| Total Debt | 14.92M | 22.93M | 23.51M | 62.94M | 1.70M |
| Total Liabilities | 26.94M | 38.99M | 51.39M | 74.21M | 5.78M |
| Stockholders Equity | 2.48M | 9.28M | 21.80M | 18.44M | 41.22M |
Cash Flow | |||||
| Free Cash Flow | -24.80M | -23.94M | -16.13M | -17.03M | -21.82M |
| Operating Cash Flow | -24.75M | -23.60M | -14.87M | -16.43M | -20.51M |
| Investing Cash Flow | 9.90M | -1.43M | -9.00M | -25.04M | 18.70M |
| Financing Cash Flow | 13.61M | 26.09M | -1.30M | 56.90M | 232.00K |
Avacta Group plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | £116.37M | -18.11 | 90.29% | ― | ― | 69.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £299.78M | -6.87 | -2929.47% | ― | ― | ― | |
50 Neutral | £290.32M | -0.60 | -31.83% | ― | -5.89% | -310.69% | |
46 Neutral | £22.47M | 33.81 | 14.26% | ― | ― | ― | |
43 Neutral | £3.68M | 4.70 | -83.53% | ― | ― | 93.02% | |
43 Neutral | £85.17M | -5.05 | -116.21% | ― | 81.46% | -15.88% |
* Healthcare Sector Average
GB:AVCT
Avacta Group plc
64.00
13.30
26.23%
GB:NFX
Nuformix Plc
0.14
0.05
56.67%
GB:PRTC
PureTech Health
118.80
-16.20
-12.00%
GB:SCLP
Scancell Holdings
9.60
-0.90
-8.57%
GB:4BB
4basebio UK Societas
550.00
-340.00
-38.20%
GB:AREC
Arecor Therapeutics PLC
59.50
-4.00
-6.30%
Avacta Group plc Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Avacta Cuts Convertible Bond Principal with Accelerated Cash Repayment
Positive
Jul 9, 2026
Avacta Group plc has received an accelerated payment notice from its convertible bond holder for the deferred January 2026 quarterly installment and has chosen to settle the obligation in cash. The company has paid £3.67 million, covering ...
Business Operations and StrategyExecutive/Board Changes
Avacta Strengthens Board With Appointment of Patrick Vink as Deputy Chairman
Positive
Jul 8, 2026
Avacta Therapeutics has appointed seasoned healthcare executive Dr. Patrick Vink as Non-Executive Deputy Chairman and Senior Independent Director, strengthening the board as the company advances its oncology pipeline. Vink brings extensive experie...
Business Operations and StrategyProduct-Related Announcements
Avacta Data Underscore Broad Potential of pre|CISION Cancer Platform
Positive
Jun 25, 2026
Avacta Therapeutics has reported new clinical and translational data for its pre|CISION-enabled chemotherapy faridoxorubicin in salivary gland cancer and soft tissue sarcoma. The results, presented at the BIO International Convention, show robust ...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Avacta Wins FDA Backing for Single Pivotal Trial of AVA6000 in Salivary Gland Cancer
Positive
Jun 25, 2026
Avacta has secured agreement from the U.S. Food and Drug Administration on the design of a single pivotal trial for faridoxorubicin (AVA6000) in salivary gland cancer, using progression-free survival as the sole primary endpoint for potential full...
Business Operations and StrategyShareholder Meetings
Avacta Wins Strong Shareholder Backing as All AGM Resolutions Pass
Positive
Jun 23, 2026
Avacta Therapeutics reported that all resolutions at its Annual General Meeting were passed, with strong shareholder support across the ballot items. The outcome underscores broad investor backing for the company’s current strategy and gover...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingProduct-Related Announcements
Avacta Extends Cash Runway as pre|CISION Oncology Pipeline Advances
Positive
Jun 22, 2026
Avacta reported strong year-to-date progress in 2026, advancing its pre|CISION-based oncology pipeline and highlighting clinical and preclinical milestones across its Gen One, Gen Two and Gen Three programs. The company initiated patient dosing in...
Business Operations and StrategyPrivate Placements and Financing
Avacta Raises £9m to Cut Convertible Debt and Fund Oncology Pipeline
Positive
Jun 5, 2026
Avacta Group has raised approximately £9 million in an oversubscribed equity placing, issuing about 12.8 million new shares at 70 pence each, alongside a small director subscription, to strengthen its balance sheet. The fundraise targets repa...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance
Avacta applies for AIM block listing to cover employee share options
Neutral
Jun 1, 2026
Avacta has applied for a block listing of 5,500,000 new ordinary shares on AIM to cover potential share issues arising from the exercise of employee options under its long-term incentive and share option schemes. The new shares will be issued from...
Business Operations and StrategyProduct-Related Announcements
Avacta Reports Strong Early Efficacy and Cardiac Safety for AVA6000 in Salivary Gland Cancer
Positive
Jun 1, 2026
Avacta Therapeutics has reported updated Phase 1a/1b data for its lead candidate faridoxorubicin (AVA6000), a pre|CISION-enabled form of doxorubicin, showing encouraging safety and early efficacy in salivary gland cancers presented at the ASCO 202...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Avacta reshapes board leadership as oncology pipeline advances
Positive
May 29, 2026
Avacta Therapeutics has announced that non-executive director Richard Hughes will become non-executive chairman following the company’s annual general meeting on 22 June 2026, succeeding Shaun Chilton, who will step down from the board but r...
Financial DisclosuresShareholder Meetings
Avacta publishes 2025 annual report and sets June AGM with online business update
Neutral
May 29, 2026
Avacta Therapeutics has published its Annual Report and Accounts for the year ended 31 December 2025, along with the notice of its upcoming Annual General Meeting, on the company’s website. Printed copies are being mailed to shareholders who...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingProduct-Related Announcements
Avacta advances pre|CISION oncology pipeline and extends cash runway into 2027
Positive
May 19, 2026
Avacta reported significant RD progress in 2025, advancing three generations of its pre|CISION platform, with AVA6000 and AVA6103 now in clinical development and AVA6207 moving through preclinical dual-payload work. The company highlighted encoura...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.